The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Open accessAbstract
Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers. In this phase II/III trial (EudraCT 2004‐000723‐15; NCT00836654), cancer patients (n = 258) with recurrent symptomatic malignant ascites resistant to conventional chemotherapy were randomized to paracentesis plus catumaxomab (catumaxomab) or paracentesis alone (control) and stratified by cancer type (129 ovarian and 129 nonovarian). Catumaxomab was administered as an i.p. infusion on Days 0, 3, 7 and 10 at doses of 10, 20, 50 and 150 μg, respectively. The primary efficacy endpoint was puncture‐free survival. Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and overall survival (OS). Puncture‐free survival was significantly longer in the catumaxomab group (median 46 days) than the control group (median 11 days) (hazard ratio = 0.254: p < 0.0001) as was median time to next paracentesis (77 versus 13 days; p < 0.0001). In addition, catumaxomab patients had fewer signs and symptoms of ascites than control patients. OS showed a positive trend for the catumaxomab group and, in a prospectively planned analysis, was significantly prolonged in patients with gastric cancer (n = 66; 71 versus 44 days; p = 0.0313). Although adverse events associated with catumaxomab were frequent, they were manageable, generally reversible and mainly related to its immunologic mode of action. Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1932) · Medical Entomology and Zoology · Cited by 9,568
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Cancer: Principles and Practice of Oncology
CLAUDINO, W. M., & BIGANZOLI, L. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00680.x · Cited by 855
Frequent EpCam protein expression in human carcinomas
Went, P. T. H., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., & Dirnhofer, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.08.026 · Cited by 819
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Ayantunde, A. A., & Parsons, S. L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl499 · Cited by 385
Self-citationMalignant ascites: Systematic review and guideline for treatment
Becker, G., Galandi, D., & Blum, H. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.018 · Cited by 349
Burges, A., Wimberger, P., Kümper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., Pfisterer, J., Lichinitser, M., Makhson, A., Moiseyenko, V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2769 · Cited by 257
Self-citationMalignant Ascites: Clinical and Experimental Observations
GARRISON, R. N., KAELIN, L. D., HEUSER, L. S., & GALLOWAY, R. H. (1986) · Annals of Surgery · doi:10.1097/00000658-198606000-00009 · Cited by 208
Zeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189
Self-citationInduction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174
Self-citationThe Current and Future Management of Malignant Ascites
Smith, E. M., & Jayson, G. C. (2003) · Clinical Oncology · doi:10.1053/clon.2002.0135 · Cited by 167
Immunotherapy of malignant ascites with trifunctional antibodies
Heiss, M. M., Ströhlein, M. A., Jäger, M., Kimmig, R., Burges, A., Schoberth, A., Jauch, K., Schildberg, F., & Lindhofer, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21165 · Cited by 117
Self-citationRuf, P., Gires, O., Jäger, M., Fellinger, K., Atz, J., & Lindhofer, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603881 · Cited by 102
Self-citationIntraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
Hamilton, C. A., Maxwell, G. L., Chernofsky, M. R., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.028 · Cited by 86
McLaughlin, P. M. J., Harmsen, M. C., Dokter, W. H. A., Kroesen, B., van der Molen, H., Brinker, M. G. L., Hollema, H., Ruiters, M. H. J., Buys, C. H. C. M., & de Leij, L. F. M. H. (2001) · PubMed · Cited by 67
PRANDOTA, J. (2005) · PubMed · Cited by 65
Marmé, A., Strauß, G., Bastert, G., Grischke, E., & Moldenhauer, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10562 · Cited by 58
General aspects of cytokine-release syndrome: timing and incidence of symptoms.
Jeyarajah, D. R., & Thistlethwaite, J. R. (1993) · PubMed · Cited by 56
Diaz‐Arias, A. A., Loy, T. S., Bickel, J. T., & Chapman, R. K. (1993) · Diagnostic Cytopathology · doi:10.1002/dc.2840090509 · Cited by 56
Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects
Ayhan, A., Gültekin, M., Taşkıran, Ç., Dursun, P., Fırat, P., Bozdağ, G., Çelik, N., & Yuce, K. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00777.x · Cited by 56
The past, the present and future of the OK-432 therapy for patients with malignant effusions.
Katano, M., & Morisaki, T. (1998) · PubMed · Cited by 52
Intraperitoneal interferon in the management of malignant ascites
Stuart, G. C. E., Nation, J. G., Snider, D. D., & Thunberg, P. (1993) · Cancer · Cited by 46
The Pathogenesis of Malignant Ascites
Tamsma, J. T. (2007) · Springer eBooks · doi:10.1007/978-0-387-48993-3_6 · Cited by 27
Hirte, H. W., Miller, D., Tonkin, K. S., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1996.4529 · Cited by 25
Molema, G., Tervaert, J. W. C., Kroesen, B. J., Helfrich, W., Meijer, D. K. F., & de Leij, L. F. M. H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0945 · Cited by 25
Characterization of human IgG antimouse antibody in patients with B-cell malignancies.
DeNardo, G. L., Mirick, G. R., Kroger, L. A., Bradt, B. M., Lamborn, K. R., & DeNardo, S. J. (2003) · PubMed · Cited by 10
Bokemeyer, C., Heiss, M., Gamperl, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3036 · Cited by 10
Self-citation
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Metadata
- Authors
- Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., Ganea‐Motan, E., Ciuleanu, T., Wimberger, P., Schmittel, A., Schmalfeldt, B., Burges, A., Bokemeyer, C., Lindhofer, H., Lahr, A., & Parsons, S. L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-08-26
- Volume
- 127
- Issue
- 9
- Pages
- 2209-2221
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2038476799
- Cited by
- 549
- References
- 28
- FWCI
- 40.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.